300630 普利制药
已收盘 07-08 15:00:00
资讯
新帖
简况
7月8日普利制药(300630)龙虎榜数据:机构净卖出494.0万元,北向资金净买入217.66万元
证券之星 · 17:14
7月8日普利制药(300630)龙虎榜数据:机构净卖出494.0万元,北向资金净买入217.66万元
年报“难产”!医药“白马股”收罚单再次被立案,复牌暴跌20%!
格隆汇 · 15:00
年报“难产”!医药“白马股”收罚单再次被立案,复牌暴跌20%!
普利制药(300630.SZ):正在被中国证监会立案调查
智通财经 · 07:02
普利制药(300630.SZ):正在被中国证监会立案调查
图解普利制药一季报:第一季度单季净利润同比增0.44%
证券之星 · 07-06 01:42
图解普利制药一季报:第一季度单季净利润同比增0.44%
图解普利制药年报:第四季度单季净利润同比减98.36%
证券之星 · 07-06 00:31
图解普利制药年报:第四季度单季净利润同比减98.36%
普利制药最新公告:子公司药用辅料磺丁基倍他环糊精钠获得CEP证书
证券之星 · 07-04
普利制药最新公告:子公司药用辅料磺丁基倍他环糊精钠获得CEP证书
普利制药(300630.SZ):药用辅料磺丁基倍他环糊精钠获得CEP证书
智通财经 · 07-04
普利制药(300630.SZ):药用辅料磺丁基倍他环糊精钠获得CEP证书
普利制药(300630.SZ):抗真菌类药物泊沙康唑注射液获得国家药品监督管理局(NMPA)上市许可
智通财经 · 06-30
普利制药(300630.SZ):抗真菌类药物泊沙康唑注射液获得国家药品监督管理局(NMPA)上市许可
普利制药最新公告:泊沙康唑注射液获得国家药品监督管理局(NMPA)上市许可
证券之星 · 06-30
普利制药最新公告:泊沙康唑注射液获得国家药品监督管理局(NMPA)上市许可
普利制药最新公告:公司自查整改工作尚在进行中
证券之星 · 06-28
普利制药最新公告:公司自查整改工作尚在进行中
普利制药最新公告:注射用达托霉素获以色列上市许可
证券之星 · 06-26
普利制药最新公告:注射用达托霉素获以色列上市许可
普利制药(300630.SZ):注射用达托霉素获以色列卫生部药剂司上市许可
智通财经 · 06-26
普利制药(300630.SZ):注射用达托霉素获以色列卫生部药剂司上市许可
多家公募出手,调整普利制药估值,兴银基金旗下多只产品一季度末仍重仓持有
每日经济新闻 · 06-26
多家公募出手,调整普利制药估值,兴银基金旗下多只产品一季度末仍重仓持有
普利制药(300630.SZ):钆特酸葡胺注射液获上市许可
智通财经网 · 06-25
普利制药(300630.SZ):钆特酸葡胺注射液获上市许可
普利制药最新公告:钆特酸葡胺注射液获NMPA上市许可
证券之星 · 06-25
普利制药最新公告:钆特酸葡胺注射液获NMPA上市许可
普利制药最新公告:伏立康唑注射液获得丹麦药品管理局(DKMA)上市许可
证券之星 · 06-24
普利制药最新公告:伏立康唑注射液获得丹麦药品管理局(DKMA)上市许可
普利制药(300630.SZ):伏立康唑注射液获丹麦上市许可
智通财经 · 06-24
普利制药(300630.SZ):伏立康唑注射液获丹麦上市许可
普利制药(300630.SZ):注射用盐酸多西环素获美国FDA上市许可
智通财经 · 06-23
普利制药(300630.SZ):注射用盐酸多西环素获美国FDA上市许可
普利制药最新公告:注射用盐酸多西环素获得美国FDA上市许可
证券之星 · 06-23
普利制药最新公告:注射用盐酸多西环素获得美国FDA上市许可
加载更多
公司概况
公司名称:
海南普利制药股份有限公司
所属行业:
医药制造业
上市日期:
2017-03-28
主营业务:
海南普利制药股份有限公司的主营业务为药物研发、注册、生产和销售;公司的主要产品有左乙拉西坦注射用浓溶液、注射用比伐芦定、注射用阿奇霉素、注射用伏立康唑、注射用更昔洛韦、注射用泮托拉唑钠、注射用盐酸万古霉素、硝普钠注射液、依替巴肽注射液、特利加压素注射液、左氧氟沙星片、地氯雷他定片、双环胺注射液、地氯雷他定干混悬剂、阿奇霉素干混悬剂、氟康唑干混悬剂、伏立康唑干混悬剂、磷酸奥司他韦胶囊、拉考沙胺注射液、苯磺顺阿曲库铵注射液等产品公司现已发展成为中国上市公司科技创新百强企业,是中国医药企业制剂国际化先导企业,被国家工信部纳入2016年工业转型升级中国制造2025儿童药基地,是海南省医药行业优秀企业。荣获2023年度海南省企业100强、2023年合成生物学产业价值金榜“TOP6”、2022年度中国化药企业“TOP100”、2023年中国医药工业最具投资价值企业、2023年“中国消费-卫生健康医药行业影响力品牌”。
发行价格:
11.49
{"stockData":{"symbol":"300630","market":"SZ","secType":"STK","nameCN":"普利制药","latestPrice":9.88,"timestamp":1720422216000,"preClose":12.35,"halted":0,"volume":5294500,"delay":0,"floatShares":338000000,"shares":451999999,"eps":0.1909,"marketStatus":"已收盘","marketStatusCode":5,"change":-2.47,"latestTime":"07-08 15:00:00","open":9.88,"high":9.88,"low":9.88,"amount":52309700,"amplitude":0,"askPrice":9.88,"askSize":280763,"bidPrice":0,"bidSize":0,"shortable":0,"etf":0,"ttmEps":0.1909,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1720488600000},"adr":0,"adjPreClose":12.35,"symbolType":"stock","openAndCloseTimeList":[[1720402200000,1720409400000],[1720414800000,1720422000000]],"highLimit":13.59,"lowLimit":11.12,"ibTradeSell":false,"ibTradeBuySell":false,"totalEquity":451775165,"pbRate":1.85,"roa":"--","roe":"2.19%","epsLYR":0.2,"marketValue":4464000000,"floatMarketCap":3342000000,"peRate":51.754846,"changeRate":-0.2,"turnoverRate":0.0157,"status":1},"requestUrl":"/m/hq/s/300630","defaultTab":"news","newsList":[{"id":"2449721443","title":"7月8日普利制药(300630)龙虎榜数据:机构净卖出494.0万元,北向资金净买入217.66万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2449721443","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2449721443?lang=zh_cn&edition=full","pubTime":"2024-07-08 17:14","pubTimestamp":1720430071,"startTime":"0","endTime":"0","summary":"证券之星消息,沪深交易所2024年7月8日公布的交易公开信息显示,普利制药因日跌幅达到15%的前5只证券登上龙虎榜。此次是近5个交易日内第1次上榜。截至2024年7月8日收盘,普利制药报收于9.88元,下跌20.0%,跌停,换手率1.57%,成交量5.29万手,成交额5230.97万元。从龙虎榜公布的当日买卖数据来看,机构合计净卖出494.0万元,北向资金合计净买入217.66万元。从龙虎榜数据可以发现和研究机构、游资和散户的资金动向。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024070800024014.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300630","BK0239"],"gpt_icon":0},{"id":"2449744760","title":"年报“难产”!医药“白马股”收罚单再次被立案,复牌暴跌20%!","url":"https://stock-news.laohu8.com/highlight/detail?id=2449744760","media":"格隆汇","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2449744760?lang=zh_cn&edition=full","pubTime":"2024-07-08 15:00","pubTimestamp":1720422026,"startTime":"0","endTime":"0","summary":"年内第二次遭证监会立案","market":"hk","thumbnail":"https://img3.gelonghui.com/a0981-62b5976e-7506-47e5-be17-4f1674bf589c.jpg?guru_height=1280&guru_width=1280","type":0,"news_type":0,"thumbnails":["https://img3.gelonghui.com/a0981-62b5976e-7506-47e5-be17-4f1674bf589c.jpg?guru_height=1280&guru_width=1280"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.gelonghui.com/p/837439","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"gelonghui_highlight","symbols":["09939","BK1515","BK1161","300630","BK1574","BK0239"],"gpt_icon":0},{"id":"2449796970","title":"普利制药(300630.SZ):正在被中国证监会立案调查","url":"https://stock-news.laohu8.com/highlight/detail?id=2449796970","media":"智通财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2449796970?lang=zh_cn&edition=full","pubTime":"2024-07-08 07:02","pubTimestamp":1720393345,"startTime":"0","endTime":"0","summary":"智通财经APP讯,普利制药(300630.SZ)公告,公司收到中国证监会《立案告知书》。因公司涉嫌信息披露违法违规,根据相关法律法规,中国证监会决定对公司立案。前期因公司2021年、2022年年度报告中营业收入、利润等财务信息披露不准确,被要求进行相关自查整改工作。根据自查,公司对2021年、2022年合并财务报表和母公司财务报表进行会计差错更正及追溯调整,上述会计差错更正及追溯调整涉及多个会计年度且金额较大。目前,公司正在被中国证监会立案调查。若后续经中国证监会行政处罚认定的事实,公司触及重大违法强制退市情形,公司股票将被实施重大违法强制退市。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1146638.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0239","300630"],"gpt_icon":0},{"id":"2449182572","title":"图解普利制药一季报:第一季度单季净利润同比增0.44%","url":"https://stock-news.laohu8.com/highlight/detail?id=2449182572","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2449182572?lang=zh_cn&edition=full","pubTime":"2024-07-06 01:42","pubTimestamp":1720201332,"startTime":"0","endTime":"0","summary":"证券之星消息,普利制药2024年一季报显示,公司主营收入3.06亿元,同比上升42.69%;归母净利润6669.05万元,同比上升0.44%;扣非净利润6426.74万元,同比上升0.46%;负债率54.94%,投资收益0.0万元,财务费用910.73万元,毛利率75.77%。财报数据概要请见下图: 以上内容由证券之星根据公开信息整理,由算法生成(网信算备310104345710301240019号),与本站立场无关,如数据存在问题请联系我们。本文为数据整理,不对您构成任何投资建议,投资有风险,请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024070600001585.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300630"],"gpt_icon":0},{"id":"2449729057","title":"图解普利制药年报:第四季度单季净利润同比减98.36%","url":"https://stock-news.laohu8.com/highlight/detail?id=2449729057","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2449729057?lang=zh_cn&edition=full","pubTime":"2024-07-06 00:31","pubTimestamp":1720197080,"startTime":"0","endTime":"0","summary":"证券之星消息,普利制药2023年年报显示,公司主营收入13.04亿元,同比下降19.43%;归母净利润8592.29万元,同比下降70.87%;扣非净利润-1256.74万元,同比下降104.61%;其中2023年第四季度,公司单季度主营收入-4775.09万元,同比下降119.22%;单季度归母净利润-3.18亿元,同比下降98.36%;单季度扣非净利润-3.65亿元,同比下降122.8%;负债率53.77%,投资收益440.27万元,财务费用4731.6万元,毛利率73.05%。本文为数据整理,不对您构成任何投资建议,投资有风险,请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024070600000228.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300630"],"gpt_icon":0},{"id":"2448445810","title":"普利制药最新公告:子公司药用辅料磺丁基倍他环糊精钠获得CEP证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2448445810","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2448445810?lang=zh_cn&edition=full","pubTime":"2024-07-04 18:10","pubTimestamp":1720087845,"startTime":"0","endTime":"0","summary":"普利制药公告,子公司安徽普利药业有限公司已于近日收到欧洲药品质量管理局(EDQM)签发的药用辅料磺丁基倍他环糊精钠欧洲药典适用性认证(CEP)证书。以上内容由证券之星根据公开信息整理,由算法生成(网信算备310104345710301240019号),与本站立场无关,如数据存在问题请联系我们。本文为数据整理,不对您构成任何投资建议,投资有风险,请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024070400035612.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300630"],"gpt_icon":0},{"id":"2448443223","title":"普利制药(300630.SZ):药用辅料磺丁基倍他环糊精钠获得CEP证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2448443223","media":"智通财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2448443223?lang=zh_cn&edition=full","pubTime":"2024-07-04 18:09","pubTimestamp":1720087755,"startTime":"0","endTime":"0","summary":"智通财经APP讯,普利制药(300630.SZ)公告,公司子公司安徽普利药业有限公司已于近日收到欧洲药品质量管理局(简称“EDQM”)签发的药用辅料磺丁基倍他环糊精钠欧洲药典适用性认证(简称“CEP”)证书。磺丁基倍他环糊精是一种赋形剂,作为药用辅料可用于注射药、口服药、鼻部用药、眼部用药,对于含氮类药物具有特殊的亲和力和包合性。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1145694.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["300630","BK0239"],"gpt_icon":0},{"id":"2447712216","title":"普利制药(300630.SZ):抗真菌类药物泊沙康唑注射液获得国家药品监督管理局(NMPA)上市许可","url":"https://stock-news.laohu8.com/highlight/detail?id=2447712216","media":"智通财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2447712216?lang=zh_cn&edition=full","pubTime":"2024-06-30 17:45","pubTimestamp":1719740747,"startTime":"0","endTime":"0","summary":"智通财经APP讯,普利制药(300630.SZ)发布公告,该公司于近日收到国家药品监督管理局(以下简称“NMPA”)签发的泊沙康唑注射液的药品注册批件。公告显示,泊沙康唑注射液是一种抗真菌类药物,预防侵袭性曲霉菌和念珠菌感染。本品适用于18岁和18岁以上因重度免疫缺陷而导致这些感染风险增加的患者,例如接受造血干细胞移植(HSCT)后发生移植物抗宿主病(GVHD)的患者或化疗导致长时间中性粒细胞减少症的血液系统恶性肿瘤患者。该公司表示,公司收到了国家药品监督管理局签发的泊沙康唑注射液药品注册批件,标志着普利制药具备在中国上市销售泊沙康唑注射液的资格,将对公司拓展国内市场带来积极影响。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1143273.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0239","300630"],"gpt_icon":0},{"id":"2447679267","title":"普利制药最新公告:泊沙康唑注射液获得国家药品监督管理局(NMPA)上市许可","url":"https://stock-news.laohu8.com/highlight/detail?id=2447679267","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2447679267?lang=zh_cn&edition=full","pubTime":"2024-06-30 17:01","pubTimestamp":1719738083,"startTime":"0","endTime":"0","summary":"普利制药公告,公司于近日收到国家药品监督管理局(简称“NMPA”)签发的泊沙康唑注射液的药品注册批件。以上内容由证券之星根据公开信息整理,由算法生成(网信算备310104345710301240019号),与本站立场无关,如数据存在问题请联系我们。本文为数据整理,不对您构成任何投资建议,投资有风险,请谨慎决策。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024063000001396.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300630"],"gpt_icon":0},{"id":"2446685839","title":"普利制药最新公告:公司自查整改工作尚在进行中","url":"https://stock-news.laohu8.com/highlight/detail?id=2446685839","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2446685839?lang=zh_cn&edition=full","pubTime":"2024-06-28 22:01","pubTimestamp":1719583270,"startTime":"0","endTime":"0","summary":"普利制药公告,截至2024年6月28日,公司自查整改工作尚在进行中。公司正根据《企业会计准则第28号——会计政策、会计估计变更和差错更正》、中国证券监督管理委员会《公开发行证券的公司信息披露编制规则第19号——财务信息的更正及相关披露》等相关规定,对于自查整改工作中发现的问题进行深入分析和审慎处理,尽快完成会计差错更正,并及时披露更正后的2021年和2022年年度报告,并同步披露公司2023年年度报告和2024年第一季度报告。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024062800052710.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300630"],"gpt_icon":0},{"id":"2446352731","title":"普利制药最新公告:注射用达托霉素获以色列上市许可","url":"https://stock-news.laohu8.com/highlight/detail?id=2446352731","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2446352731?lang=zh_cn&edition=full","pubTime":"2024-06-26 17:31","pubTimestamp":1719394282,"startTime":"0","endTime":"0","summary":"普利制药公告,公司近日收到以色列卫生部药剂司签发的注射用达托霉素上市许可。以上内容由证券之星根据公开信息整理,由算法生成(网信算备310104345710301240019号),与本站立场无关,如数据存在问题请联系我们。本文为数据整理,不对您构成任何投资建议,投资有风险,请谨慎决策。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024062600035985.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300630","BK0239"],"gpt_icon":0},{"id":"2446354323","title":"普利制药(300630.SZ):注射用达托霉素获以色列卫生部药剂司上市许可","url":"https://stock-news.laohu8.com/highlight/detail?id=2446354323","media":"智通财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2446354323?lang=zh_cn&edition=full","pubTime":"2024-06-26 17:11","pubTimestamp":1719393071,"startTime":"0","endTime":"0","summary":"智通财经APP讯,普利制药(300630.SZ)发布公告,公司近日收到以色列卫生部药剂司签发的注射用达托霉素上市许可,临床用于治疗复杂性皮肤及皮肤组织感染与金黄色葡萄球菌引起的菌血症,目前注射用达托霉素已在全球广泛上市销售。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1140821.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["300630","BK0239"],"gpt_icon":0},{"id":"2446387404","title":"多家公募出手,调整普利制药估值,兴银基金旗下多只产品一季度末仍重仓持有","url":"https://stock-news.laohu8.com/highlight/detail?id=2446387404","media":"每日经济新闻","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2446387404?lang=zh_cn&edition=full","pubTime":"2024-06-26 11:24","pubTimestamp":1719372240,"startTime":"0","endTime":"0","summary":" 今日,富国基金公告称,对旗下基金持有的停牌股票“普利制药(维权)”进行估值调整,按照9.56元/股进行估值。 《每日经济新闻》记者注意到,普利制药长期被多只基金重仓——截至2021年底,多达46只基金重仓持有超过20亿元;截至今年一季度末,还有6只基金重仓持有,主要来自于兴银基金旗下的主动管理型产品。截至停牌前,普利制药收盘价为12.35元。","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/jjxw/2024-06-26/doc-inazzscn0783173.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/jjxw/2024-06-26/doc-inazzscn0783173.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["300630","BK0239"],"gpt_icon":0},{"id":"2446964897","title":"普利制药(300630.SZ):钆特酸葡胺注射液获上市许可","url":"https://stock-news.laohu8.com/highlight/detail?id=2446964897","media":"智通财经网","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2446964897?lang=zh_cn&edition=full","pubTime":"2024-06-25 17:30","pubTimestamp":1719307833,"startTime":"0","endTime":"0","summary":"智通财经APP讯,普利制药(300630.SZ)公告,公司近日收到国家药品监督管理局(简称“NMPA”)签发的钆特酸葡胺注射液的药品注册批件。钆特酸葡胺注射液是一种造影剂,仅用于疾病的诊断。更多港股重磅资讯,下载智通财经app更多港股及海外理财资讯,请点击www.zhitongcaijing.com(搜索“智通财经”);欲加入智通港股投资群,请加智通客服微信(ztcjkf)","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1140143.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["300630","BK0239"],"gpt_icon":0},{"id":"2446892010","title":"普利制药最新公告:钆特酸葡胺注射液获NMPA上市许可","url":"https://stock-news.laohu8.com/highlight/detail?id=2446892010","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2446892010?lang=zh_cn&edition=full","pubTime":"2024-06-25 17:20","pubTimestamp":1719307200,"startTime":"0","endTime":"0","summary":"普利制药公告,公司近日收到国家药品监督管理局签发的钆特酸葡胺注射液药品注册批件。该药品适用于大脑和脊髓病变、脊柱病变及其他全身性病理检查。以上内容由证券之星根据公开信息整理,由算法生成(网信算备310104345710301240019号),与本站立场无关,如数据存在问题请联系我们。本文为数据整理,不对您构成任何投资建议,投资有风险,请谨慎决策。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024062500034125.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300630","BK0239"],"gpt_icon":0},{"id":"2445073484","title":"普利制药最新公告:伏立康唑注射液获得丹麦药品管理局(DKMA)上市许可","url":"https://stock-news.laohu8.com/highlight/detail?id=2445073484","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2445073484?lang=zh_cn&edition=full","pubTime":"2024-06-24 20:00","pubTimestamp":1719230437,"startTime":"0","endTime":"0","summary":"普利制药公告,公司于近日收到丹麦药品管理局(DKMA)签发的伏立康唑注射液的上市许可。伏立康唑是一种广谱的三唑类抗真菌药,治疗侵袭性曲霉病,非中性粒细胞减少患者中的念珠菌血症。以上内容由证券之星根据公开信息整理,由算法生成(网信算备310104345710301240019号),与本站立场无关,如数据存在问题请联系我们。本文为数据整理,不对您构成任何投资建议,投资有风险,请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024062400029744.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300630"],"gpt_icon":0},{"id":"2445022980","title":"普利制药(300630.SZ):伏立康唑注射液获丹麦上市许可","url":"https://stock-news.laohu8.com/highlight/detail?id=2445022980","media":"智通财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2445022980?lang=zh_cn&edition=full","pubTime":"2024-06-24 18:54","pubTimestamp":1719226460,"startTime":"0","endTime":"0","summary":"智通财经APP讯,普利制药(300630.SZ)公告,公司于近日收到丹麦药品管理局(DKMA)签发的伏立康唑注射液的上市许可。据悉,伏立康唑是一种广谱的三唑类抗真菌药,治疗侵袭性曲霉病,非中性粒细胞减少患者中的念珠菌血症,对氟康唑耐药的念珠菌引起的严重侵袭性感染,由足放线病菌属和镰刀菌属引起的严重感染,主要用于进展性可能威胁生命的真菌感染患者的治疗,预防接受异基因造血干细胞移植(HSCT)的高危患者中的侵袭性真菌感染。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1139587.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["300630","BK0239"],"gpt_icon":0},{"id":"2445503137","title":"普利制药(300630.SZ):注射用盐酸多西环素获美国FDA上市许可","url":"https://stock-news.laohu8.com/highlight/detail?id=2445503137","media":"智通财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2445503137?lang=zh_cn&edition=full","pubTime":"2024-06-23 16:50","pubTimestamp":1719132656,"startTime":"0","endTime":"0","summary":"智通财经APP讯,普利制药(300630.SZ)发布公告,公司于近日收到美国食品药品监督管理局(简称“FDA”)签发的注射用盐酸多西环素的上市许可,注射用盐酸多西环素适用于治疗或预防已证实或强烈怀疑由易感细菌引起的感染;适用于多种微生物(立克次体属、肺炎支原体等),革兰氏阴性菌和革兰氏阳性菌引起的感染。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1139135.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0239","300630"],"gpt_icon":0},{"id":"2445039963","title":"普利制药最新公告:注射用盐酸多西环素获得美国FDA上市许可","url":"https://stock-news.laohu8.com/highlight/detail?id=2445039963","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2445039963?lang=zh_cn&edition=full","pubTime":"2024-06-23 16:31","pubTimestamp":1719131466,"startTime":"0","endTime":"0","summary":"普利制药公告,公司于近日收到美国食品药品监督管理局(FDA)签发的注射用盐酸多西环素的上市许可。注射用盐酸多西环素是四环类抗生素,国内无原研进口上市,仅两家通过一致性评价。以上内容由证券之星根据公开信息整理,由算法生成(网信算备310104345710301240019号),与本站立场无关,如数据存在问题请联系我们。本文为数据整理,不对您构成任何投资建议,投资有风险,请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024062300002375.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300630"],"gpt_icon":0}],"profile":{"ret":0,"listingDate":"2017-03-28","address":"海南省海口市美兰区桂林洋经济开发区","companyName":"海南普利制药股份有限公司","boardCode":"AI0027","perCapita":"7868股","boardName":"医药制造业","registeredCapital":"45177万元","compareEarnings":[{"period":"1week","weight":-0.0059},{"period":"1month","weight":-0.0377},{"period":"3month","weight":-0.0389},{"period":"6month","weight":0.0071},{"period":"1year","weight":-0.0798},{"period":"ytd","weight":-0.0084}],"survey":" 海南普利制药股份有限公司的主营业务为药物研发、注册、生产和销售;公司的主要产品有左乙拉西坦注射用浓溶液、注射用比伐芦定、注射用阿奇霉素、注射用伏立康唑、注射用更昔洛韦、注射用泮托拉唑钠、注射用盐酸万古霉素、硝普钠注射液、依替巴肽注射液、特利加压素注射液、左氧氟沙星片、地氯雷他定片、双环胺注射液、地氯雷他定干混悬剂、阿奇霉素干混悬剂、氟康唑干混悬剂、伏立康唑干混悬剂、磷酸奥司他韦胶囊、拉考沙胺注射液、苯磺顺阿曲库铵注射液等产品公司现已发展成为中国上市公司科技创新百强企业,是中国医药企业制剂国际化先导企业,被国家工信部纳入2016年工业转型升级中国制造2025儿童药基地,是海南省医药行业优秀企业。荣获2023年度海南省企业100强、2023年合成生物学产业价值金榜“TOP6”、2022年度中国化药企业“TOP100”、2023年中国医药工业最具投资价值企业、2023年“中国消费-卫生健康医药行业影响力品牌”。","serverTime":1720441712140,"listedPrice":11.49,"stockholders":"42992人(较上一季度增加2.36%)","compareStock":{"symbol":"000001.SH","name":"上证指数"}},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.24.2","shortVersion":"4.24.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"普利制药(300630)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供普利制药(300630)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"普利制药,300630,普利制药股票,普利制药股票老虎,普利制药股票老虎国际,普利制药行情,普利制药股票行情,普利制药股价,普利制药股市,普利制药股票价格,普利制药股票交易,普利制药股票购买,普利制药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"普利制药(300630)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供普利制药(300630)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}